A new frontier of cancer research is being explored by Queen’s Health Sciences (QHS). Join three of the pioneers: Drs. Jacqueline Galica, Annette Hay, and Bishal Gyawali. From cutting-edge treatments and patient trials to cancer policy and survivorship, join these groundbreaking researchers for a crucial look at the future of cancer care, treatment, research.
Dr. Jane Philpott, QHS Dean and former health minister, will serve as moderator as our trio of experts take the audience behind the frontlines of this rapidly-evolving – and game-changing – field.
Please consider making a donation to support Queen's Health Sciences. Make a gift
Meet the panel
Dr. Jacqueline Galica is an assistant professor at the School of Nursing, Queen’s University, and a member of the Queen’s Cancer Research Institute in the Division of Cancer Care and Epidemiology. After earning her Bachelor of Science in Nursing (BScN) from Toronto Metropolitan University, Dr. Galica worked as a clinical trials nurse coordinator at Princess Margaret Hospital in Toronto. In this role, Dr. Galica saw the need for better cancer treatments and patient care practices which led her to her current areas of research: preparing for transitions along the cancer trajectory, gaining insights into the cancer experience, and understanding compassionate care.
Dr. Bishal Gyawali is an associate professor in Medical Oncology and Public Health Sciences, and a scientist in the Division of Cancer Care and Epidemiology, Queen’s University. He is also an affiliated faculty member in the Department of Medicine at Brigham and Women’s Hospital in Boston. Dr. Gyawali belongs to editorial and advisory boards of multiple medicine and oncology journals. His areas of academic interest include cancer policy, evidence-based oncology, financial toxicities of cancer treatment, clinical trial methods, supportive care, and global oncology. Dr. Gyawali is also a member of the World Health Organization’s Essential Medicine List for Cancer Drugs, and his current research areas focus on the impact of health technology assessments on approval and funding decisions for cancer drugs, cancer policy and the economic consequences of therapies, and addressing disparities in cancer care.
Dr. Annette Hay is the chair of the Division of Hematology within the Department of Medicine, Queen’s University, cross-appointed to the Departments of Oncology and Pediatrics, and a senior investigator with the Canadian Cancer Trials Group (CCTG), located at Queen’s. A graduate of the University of Dundee, Dr. Hay completed her medical and hematology training in Scotland. In 2012 she undertook a 30-month fellowship with the CCTG, moving into a senior investigator role two years later. Dr. Hay’s clinical practice includes all areas of Hematology, with special interest in hematological malignancies and her research spans clinical trial design, conduct, and analysis for patients with lymphoma, leukemia, myeloma, and myelodysplasia.
Meet the moderator
Dr. Jane Philpott is the Dean of the Faculty of Health Sciences, Director of the School of Medicine at Queen's University, and CEO of the Southeastern Ontario Academic Medical Organization. She is a medical doctor, a Professor of Family Medicine, and former Member of Parliament. Prior to politics, Jane spent the first decade of her medical career in Niger, West Africa. She was a family doctor in Markham-Stouffville for 17 years and became Chief of Family Medicine at Markham Stouffville Hospital in 2008. From 2015 to 2019 she served as federal Minister of Health, Minister of Indigenous Services, President of the Treasury Board and Minister of Digital Government. She currently serves as the Ministers' Special Advisor for the Ontario Health Data Platform and was recently elected to the Canadian Academy of Health Sciences.